Merit Medical Systems (NASDAQ:MMSI) Updates FY 2026 Earnings Guidance

Merit Medical Systems (NASDAQ:MMSI) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 4.010-4.150 for the period, compared to the consensus earnings per share estimate of 3.930. The company issued revenue guidance of $1.6 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Canaccord Genuity Group cut their price objective on Merit Medical Systems from $99.00 to $90.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. Barrington Research cut their price objective on Merit Medical Systems from $109.00 to $107.00 and set an “outperform” rating for the company in a research report on Monday, April 20th. BTIG Research assumed coverage on Merit Medical Systems in a research report on Friday, February 6th. They issued a “buy” rating and a $107.00 price objective for the company. Robert W. Baird set a $83.00 price objective on Merit Medical Systems in a research report on Friday. Finally, Wall Street Zen cut Merit Medical Systems from a “strong-buy” rating to a “buy” rating in a research report on Sunday, April 5th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $93.30.

Merit Medical Systems Stock Performance

Shares of NASDAQ MMSI traded down $6.17 during trading hours on Friday, reaching $62.01. 2,526,187 shares of the stock were exchanged, compared to its average volume of 777,070. The firm has a market capitalization of $3.70 billion, a price-to-earnings ratio of 29.25, a P/E/G ratio of 1.83 and a beta of 0.64. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.95 and a current ratio of 4.34. Merit Medical Systems has a 52 week low of $61.31 and a 52 week high of $100.19. The stock’s fifty day simple moving average is $70.68 and its 200 day simple moving average is $79.78.

Merit Medical Systems (NASDAQ:MMSI) last announced its earnings results on Tuesday, February 24th. The medical instruments supplier reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.96 by $0.08. The company had revenue of $393.94 million for the quarter, compared to analyst estimates of $390.77 million. Merit Medical Systems had a return on equity of 13.82% and a net margin of 8.48%.The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.93 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. Sell-side analysts predict that Merit Medical Systems will post 3.61 EPS for the current year.

More Merit Medical Systems News

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Q1 results beat and management raised guidance — Merit reported Q1 non‑GAAP EPS of $0.94 (vs. $0.84 est.) and revenue of ~$382M (beat). The company lifted FY2026 EPS guidance to $4.01–$4.15 and reiterated revenue targets, pointing to steady segment/geographic gains and improved margins and free cash flow. Press Release
• Positive Sentiment: Operational highlights support durable cash generation — Management reported GAAP operating margin ~11.6%, non‑GAAP operating margin ~19.7%, and free cash flow up ~26%. These metrics support the company’s cash‑flow story and capital deployment (recent acquisition activity). Details
• Positive Sentiment: Acquisition expands product set — Merit closed the View Point Medical acquisition (OneMark detection/tissue marker products) for $140M (cash portion $90M), and divested the DualCap line for $28M; these moves can bolster higher‑margin therapeutic offerings. Transaction Details
• Neutral Sentiment: Earnings call / transcripts available — Call transcripts and highlights confirm beat and management commentary on organic growth, mix, and margin drivers; useful for investors who want management color. Earnings Call Transcript
• Negative Sentiment: Analysts trimmed price targets — Several firms cut PTs today (JPMorgan: $95→$77, Wells Fargo: $78→$74, Needham: $101→$90). Although ratings were maintained (overweight/equal weight/buy), the cuts reflect multiple‑compression or sector re‑rating concerns and likely contributed to selling pressure. Analyst Notes (Benzinga)
• Negative Sentiment: Market reaction driven by valuation vs. growth — Despite beats, some analysts flagged growth deceleration and applied lower sector multiples; with the stock already well off its 52‑week high, target trims can trigger headline-driven outflows. Analyst Commentary

Hedge Funds Weigh In On Merit Medical Systems

A number of large investors have recently made changes to their positions in the company. State Street Corp increased its stake in shares of Merit Medical Systems by 1.5% during the fourth quarter. State Street Corp now owns 2,231,048 shares of the medical instruments supplier’s stock worth $196,645,000 after purchasing an additional 32,459 shares during the period. Fuller & Thaler Asset Management Inc. increased its stake in Merit Medical Systems by 12.7% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 2,077,796 shares of the medical instruments supplier’s stock worth $183,137,000 after acquiring an additional 234,682 shares during the period. Wellington Management Group LLP increased its stake in Merit Medical Systems by 7.0% during the 4th quarter. Wellington Management Group LLP now owns 1,327,013 shares of the medical instruments supplier’s stock worth $116,963,000 after acquiring an additional 86,504 shares during the period. Dimensional Fund Advisors LP increased its stake in Merit Medical Systems by 4.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,225,013 shares of the medical instruments supplier’s stock worth $107,974,000 after acquiring an additional 47,151 shares during the period. Finally, Morgan Stanley increased its stake in Merit Medical Systems by 17.6% during the 4th quarter. Morgan Stanley now owns 1,140,390 shares of the medical instruments supplier’s stock worth $100,514,000 after acquiring an additional 170,517 shares during the period. Institutional investors own 99.66% of the company’s stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.